Clever Culture Systems Limited
CC5.AX
Australian Securities Exchange0.02
AUD
- -
- -
Clever Culture Systems Limited
CC5.AX
(Australian Securities Exchange)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Clever Culture Systems Limited operates as a biotech hardware and automated microbiology solutions provider focused on intelligent culture plate analysis and laboratory automation. The company specializes in automated imaging and interpretation of culture plates, AI-driven modules for microbial growth analysis, and accompanying software libraries and publications to support microbiology research and clinical diagnostics. Headquartered in Adelaide, Australia, Clever Culture Systems was founded in 2013 and maintains operations in Australia with regional exposure to international markets; it includes product families such as APAS Independence, APAS Modules, and a Scientific Library, leveraging AI technology to streamline culture-based workflows and data generation for researchers and healthcare customers. Main products and services - APAS Independence: autonomous imaging and analysis system for culture plates, enabling non-invasive monitoring, colony counting, and growth assessment with AI-driven interpretation. - APAS Modules: modular add-ons and software components that extend the capabilities of the core APAS platform, including enhanced analytics, workflow automation, and interoperability with laboratory instruments. - Scientific Library: curated collection of publications, case studies, and references to microbiology research and culture-based assays to support scientific workflows. - Laboratory automation software: end-to-end software solutions that orchestrate automated handling, imaging, and data capture within microbiology labs. - AI-enabled culture analysis tools: machine-learning-based algorithms for colony detection, growth profiling, and anomaly identification to improve accuracy and throughput. Latest major company changes - Strategic alliances and partnerships: engages in collaborations to expand capabilities in automated imaging, AI-driven analysis, and laboratory workflow integration for microbiology and clinical diagnostics. - Product development and launches: continues to advance APAS platform modules and ancillary software to broaden automated culture analysis capabilities and integrate with broader lab information systems. - Business expansion and reorganizations: experiences organizational and market expansion activity over the last 1–2 years, with focus on scaling operations and widening geographic reach in alignment with international demand for automated microbiology solutions. - Acquisitions and investments: has seen acquisitions and funding activity related to strengthening its technology stack and go-to-market capabilities, including integration with complementary AI and automation technologies. - Corporate branding and presence: maintains a formal corporate presence with ongoing participation in international biotech events to showcase capabilities and secure partnerships. Additional context - Industry and business segments: biotechnology equipment and laboratory automation; microbial growth analysis; AI-enabled diagnostic tooling; research and development services. - Target markets: research laboratories, pharmaceutical and biotech companies, clinical and diagnostic laboratories, and academic institutions requiring automated culture handling and analysis. - Geographic footprint: primarily based in Australia with international partner and customer engagement across North America, Europe, and Asia-Pacific regions where applicable. - Subsidiaries and parent relationships: operates as an independent company with established partnerships and potential affiliate arrangements in related geographies; no explicit parent company disclosed.